Fda approves trikafta to treat the underlying cause of cystic fibrosis in people ages 12 and older who have at least one f508del mutation

Fda approves trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to treat the underlying cause of cystic fibrosis in people ages 12 and older who have at least one f508del mutation.vertex pharmaceuticals - submitted maa to european medicines agency (ema) for elexacaftor/tezacaftor/ivacaftor combination regimen.
VRTX Ratings Summary
VRTX Quant Ranking